Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.41 |
| ▸ | F10 | P00742 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068496 | 0.89 | KMT2A (0.57) | KMT2ADPP4MMP12LNPEPF10 | |
| SCHEMBL1748263 | 0.89 | KMT2A (0.57) | KMT2ADPP4MMP12LNPEPF10 | |
| SCHEMBL4222934 | 0.85 | KMT2A (0.48) | KMT2ADPP4LNPEPF10PRSS1 | |
| SCHEMBL13752641 | 0.85 | DPP4 (0.40) | KMT2ADPP4MMP12LNPEPF10 | |
| SCHEMBL28325731 | 0.83 | KMT2A (0.74) | KMT2ADPP4PRSS1NPC1MEN1 | |
| SCHEMBL4227356 | 0.82 | KMT2A (0.51) | KMT2ADPP4F10PRSS1F2 | |
| SCHEMBL28326830 | 0.81 | KMT2A (0.62) | KMT2ADPP4NPC1MEN1RAB9A | |
| SCHEMBL6031378 | 0.79 | NPC1 (0.58) | KMT2ADPP4MMP12F10PRSS1 | |
| SCHEMBL1748086 | 0.79 | NPC1 (0.58) | KMT2ADPP4MMP12F10PRSS1 | |
| SCHEMBL4221485 | 0.78 | MMP12 (0.41) | MMP12F10PRSS1F2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1874317-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113919-A2 | ARYL ALKYL ACID DERIVATIVES FOR AND USE THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | KMT2A 627/4885DPP4 264/4885MMP12 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.